Testing a new drug combo for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug combination for people with advanced colorectal cancer that has worsened after first treatment. It aims to see if adding these drugs can shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic colorectal cancer that has grown after your first treatment.
- Your tumor must be RAS/BRAF wild-type (a specific genetic type) for part of the trial.
- If your tumor is dMMR/MSI-H (a genetic subtype), you must have already tried a PD-1 inhibitor and it stopped working.
- You must have recovered from side effects of previous treatments and wait at least 4 weeks after major therapies.
- Your organs (like liver and kidneys) must be working well enough for the new drugs.
- You cannot have had previous treatment with a topoisomerase I drug or, for part 1, an anti-EGFR antibody therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies serplulimab (an immune-related drug) together with bevacizumab and chemotherapy to treat metastatic colorectal (colon) cancer that cannot be removed with surgery. It aims to see whether this combination improves outcomes and is safe.
This trial tests a new combination of targeted therapies for people with advanced colorectal cancer that has a certain genetic pattern (non-MSI-H, no BRAF V600E mutation). It aims to see if the combination can shrink tumors or slow the cancer's growth.
This trial is testing a new combination of drugs (envafolimab, cetuxima-β, and chemotherapy) for people with a specific type of advanced colorectal cancer that has not been treated yet. The goal is to see if it is safe and works well.
This trial tests a new combination of two immunotherapy drugs (HLX07 and serplulimab) plus chemotherapy versus standard treatments (pembrolizumab or serplulimab plus chemo) for people with advanced squamous non-small cell lung cancer who haven't had treatment yet. The goal is to see if the new combination works better.
This trial tests a new drug, HLX43, that targets a protein called PD-L1 on cancer cells and delivers a chemotherapy-like payload directly to them. It's for people with advanced colorectal cancer that hasn't responded to standard treatments.
This trial tests a combination of two targeted therapies (QL1706 and bevacizumab) plus standard chemotherapy for people with a specific form of metastatic colorectal cancer that has a BRAF V600E mutation and is MSS/pMMR. The goal is to see if this triplet works better than standard treatment alone.
Hear when a new Colon Cancer Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.